“The study is a garbage study; it should be retracted.” With that line, a fresh research paper on acetaminophen use in pregnancy crashed straight into the culture war over autism risk and drug safety.
RFK Jr. is not just quibbling over method; he is signaling distrust of the entire risk‑assessment machinery that underpins obstetric guidance. The contested study, led by academic epidemiologists and based on large observational cohorts, reported no statistically significant association between prenatal acetaminophen exposure and later autism diagnoses after adjusting for confounders with multivariable regression and sensitivity analyses. To many clinicians, that reads as reassurance for routine pain management in pregnancy. To RFK Jr., it looks like institutional capture.
His criticism matters less for its technical merit than for its political voltage. By branding the work “garbage,” the health secretary who has repeatedly warned pregnant women about the drug reframes a conventional null finding as evidence of bias, not safety. Patient advocates now face a familiar bind: heed a pharmacovigilance apparatus that leans on epidemiologic inference and neurodevelopmental endpoints, or follow a populist skeptic who treats every non‑signal as a cover‑up. In that tension, the study’s nuanced confidence intervals barely stand a chance.
